0001493152-26-022884
SEC filingNet loss deepened to $9.3M in Q1 2026 as pre-commercialization spending for CTx-1301 drove operating loss expansion, partially offset by EPS improvement on higher share count.
The company's lead candidate, CTx-1301 (dexmethylphenidate) for ADHD, was submitted to the FDA on July 31, 2025, with a PDUFA target action date of May 31, 2026. The FDA has requested additional chemistry, manufacturing, and controls (CMC) information, which the company is working to address. There is no assurance of approval by the PDUFA date or at all. If approved, Cingulate plans to commercialize CTx-1301 in the U.S. through a master services agreement with Indegene, with field sales support from IQVIA. The company also received a Notice of Allowance from the USPTO for a patent covering CTx-1301 in April 2026.
As a pre-revenue company, Cingulate has no approved products and has incurred cumulative losses. The company expects G&A expenses to increase as it supports potential commercialization of CTx-1301 and expands headcount. Strategic transaction opportunities could materially affect liquidity and capital resources, potentially requiring additional indebtedness or equity capital. The primary objective of the company's investment policy is liquidity and capital preservation.